Vista Pharmaceuticals Ltd
BSE:524711
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Vista Pharmaceuticals Ltd
Accounts Payable
Vista Pharmaceuticals Ltd
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vista Pharmaceuticals Ltd
BSE:524711
|
Accounts Payable
₹58.8m
|
CAGR 3-Years
1%
|
CAGR 5-Years
15%
|
CAGR 10-Years
-1%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Accounts Payable
₹35.3B
|
CAGR 3-Years
20%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Accounts Payable
₹30.4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Accounts Payable
₹67.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Accounts Payable
₹34.1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
8%
|
CAGR 10-Years
5%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Accounts Payable
₹16.8B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-3%
|
|
Vista Pharmaceuticals Ltd
Glance View
Vista Pharmaceuticals Ltd. engages in the manufacture and market of pharmaceutical products. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2003-07-21. The firm also sells the products to its related companies, which are engaged in the manufacture of formulations. The company offers over-the-counter and prescription generic drug products, consisting of tablets, capsules and liquids covering various therapeutic categories. Its products include tablet dosage forms in the United States market, such as Sulfamethoxazole & Trimethoprim, Acetaminophen, Bismuth Subsalicylate, Bismuth Subgallate, Ferrous Gluconate, Ferrous Sulfate, Pyrantel Pamoate and Isoxsuprine HCl and tablet dosage forms in the non-United States market, such as Aspirin, Atenolol, Mebendazole, Nefidipine, Quinine Sulfate, Ranitidine HCl, Magnesium Trisilicate Compound, Aluminium Hydroxide, Folic Acid and Captopril. Its capsule dosage forms in the non-United States market include Indomethacin, Piroxicam and Nefidipine.
See Also
What is Vista Pharmaceuticals Ltd's Accounts Payable?
Accounts Payable
58.8m
INR
Based on the financial report for Dec 31, 2025, Vista Pharmaceuticals Ltd's Accounts Payable amounts to 58.8m INR.
What is Vista Pharmaceuticals Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
-1%
Over the last year, the Accounts Payable growth was -13%. The average annual Accounts Payable growth rates for Vista Pharmaceuticals Ltd have been 1% over the past three years , 15% over the past five years , and -1% over the past ten years .
